The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy

National Medical Journal of China

Volumn 85, Issue 37, 2005, Pages 2601-2606

  Zhang, Cong ^a   Chen, Yi Pu ^b   Dong, Hong Rui ^b   Qiu, Chang Bin ^b  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b NONE

Author keywords

Angiotensin II; Aristolochic acid; Endothelin 1; Nephritis, interstitial

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ARISTOLOCHIC ACID; BETA 2 MICROGLOBULIN; BOSENTAN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; ENDOTHELIN RECEPTOR ANTAGONIST; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ACTIVITY; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY PARENCHYMA; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; URINARY EXCRETION;

ANIMALS; ARISTOLOCHIC ACIDS; COLLAGEN TYPE I; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE MODELS, ANIMAL; FIBROSIS; KIDNEY; KIDNEY DISEASES; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; TETRAZOLES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1; VALINE;

EID: 27644587106     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Chen W, Chen YP, Li A, et al. The clinical and pathyological exhibition of Aristolochic acid nephropathy. Natl Med J China, 2001, 81:1101-1105.
2. Cheng H, Tian XF, Dong HR, et al. The preliminary studies on the cross action between endothelin-1 and angiotensin II in kidney tissue of rats with diabetic nephropathy. Natl Med J China, 2004, 84:248-252.
3. Benigni A, Zoja C, Zatelli C, et al. Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. Kidney Int,2004, 66: 1959-1965.
4. Gao YL, Chen YP, Dong HR, et al. A rat model of chronic Aristolochic acid nephropathy and the protective effects of taurine on the early stage of the renal injury. Chin J Tradit West Med, 2003, 23 (Suppl): 109-112.
5. Zhang C, Chen YP, Dong HR, et al. Protective effects of Yishen Ruanjian San on renal tubulointerstitial fibrosis of chronic aristolochic acid nephropathy. Chin J Tradit West Med, 2005, 33:716-720.
6. Lin JM, Chen YP, Gao J, et al. Upregulation of cell adhesion molecules by edothelin-1 on human mesangial cells in vitro. Chin J Nephrol, 1997, 13: 67-69.
7. Chen YP, Sun YJ, Lin JM, et al. Research on the mechanism of endothelin inflammatory effects on human mesangial cells. Chin Med J, 1997, 110:530-534.
8. Ong ACM, Jowett TP, Firth JD, et al. An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration. Kidney Int, 1995, 48:390-401.
9. Tian XF, Tang GY, Chen YP. The effects of endothelin-1 and selective endothelin receptor-type A antagonist on human renal interstitial fibroblast in vitro. Natl Med J China, 2002, 82:5-9.
10. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension, 2001, 38 (3 Pt 2): 635-638.
11. Tian XF, Tang GY, Chen YP. Renoprotective effects of nonselective endothelin receptor antagonist bosentan on rats with interstitial fibrosis following unilateral ureteral obstruction. Natl Med J China, 2003, 83:510-514.
12. Cheng H, Tian XF, Dong HR, et al. A comparison study between bosentan and enalapril treatment in diabetic nephropathy. Chin J Nephrol, 2004, 20:154-158.
13. Zhao YN, Li JZ, Wang HY. Comparison of renoprotective effect between angiotensin II receptor antagonist and angiotensin converting enzyme inhibitor on puromycin nephropathy and their possible mechanism. Chin J Mult Organ Dis Elderly, 2002, 1:36-40.
14. Debelle FD, Nortier JL, Husson CP, et al. The renin-angiotensin system blockade does not prevent renal interstitial fibrosis induced by aristolochic acids. Kidney Int, 2004, 66:1815-1825.
15. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol, 1996, 7:2495-2508.
16. Chatziantoniou C, Dussaule JC. Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am J Physiol Renal Physiol, 2005, 289: F227-234.
17. Douthwaite JA, Johnson TS, Haylor JL, et al. Effects of transforming growth factor-beta 1 on renal extracellular matrix components and their regulating proteins. J Am Soc Nephrol, 1999, 10:2109-2119.
18. Kobayashi T, Inoue T, Okada H, et al. Connective tissue growth factor mediates the profibrotic effects of transforming growth factor-beta produced by tubular epithelial cells in response to high glucose. Clin Exp Nephrol, 2005, 9: 114-121.
19. Gupta S, Clarkson MR, Duggan J, et al. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int, 2000, 58:1389-1399.
20. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Nephrol Physiol, 2002, 283:F209-220.